Stock AKLI AKILI, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Akili, Inc.

Equities

AKLI

US00974B1070

End-of-day quote Nasdaq
Other stock markets
 06:00:00 2024-05-30 pm EDT 		5-day change 1st Jan Change
0.4206 USD +0.17% Intraday chart for Akili, Inc. +0.38% -13.65%
May. 29 PureTech Health's Akili, Virtual Therapeutics Sign Merger Deal to Launch Digital Health Company MT
May. 29 Virtual Therapeutics Corp. entered into an agreement to acquire Akili, Inc. for $35 million. CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Shareholder Alert: Ademi LLP investigates whether Akili, Inc. has obtained a Fair Price for its Public Shareholders
PR
PureTech Health's Akili, Virtual Therapeutics Sign Merger Deal to Launch Digital Health Company
MT
Virtual Therapeutics, Akili Interactive Enter Into Definitive Merger Agreement to Establish Leading Digital Health Company
BU
Virtual Therapeutics Corp. entered into an agreement to acquire Akili, Inc. for $35 million.
CI
Akili, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Earnings Flash (AKLI) AKILI Posts Q1 Revenue $383,000, vs. Street Est of $0.8M
MT
Akili Reports First Quarter 2024 Financial Results and Provides Business Update
BU
Akili Announces Amended Agreement with Shionogi, Shift in Corporate Strategy and Release Date for First Quarter 2024 Financial Results
BU
Akili, Inc. Plans to Continue to Pursue Marketing Authorization from the U.S. Food and Drug Administration for Its EndeavorOTC Product
CI
Akili, Inc. to Reduce Workforce
CI
Akili, Inc. Announces an Amendment to its Strategic Distribution Agreement with Shionogi & Co., Ltd
CI
Akili, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Akili, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
Earnings Flash (AKLI) AKILI Posts Q4 Revenue $749,000, vs. Street Est of $0.78M
MT
Akili Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
BU
PureTech Founded Entity Akili Announces Positive Results from Shionogi's Phase 3 Clinical Trial of Localized Version of Akili's EndeavorRx for Pediatric ADHD Patients in Japan
AQ
Shionogi & Co., Ltd. - Positive Results from Phase 3 Clinical trial of Digital Therapeutic App SDT-001 and Submission for Marketing Approval in Japan
AQ
Akili Announces Positive Results from Shionogi's Phase 3 Clinical Trial of Localized Version of Akili's EndeavorRx for Pediatric ADHD Patients in Japan
AQ
Sector Update: Health Care Stocks Ease Late Afternoon
MT
Akili Shares More Than Double After Submission of ADHD Treatment for Marketing Approval in Japan
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. AKLI Stock
  4. News Akili, Inc.